Kauppalehti4 天
Roche receives FDA approval for the first companion diagnostic to identify patients with ...
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be ...